𝗣𝘀𝘆𝗰𝗵𝗲𝗱𝗲𝗹𝗶𝗰 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀 𝗝𝘂𝗹𝘆 & 𝗔𝘂𝗴𝘂𝘀𝘁

While many of us had the chance to enjoy a vacation this summer, psychedelic researchers were hard at work

We've rounded up key papers from the past 2 months 👇

https://blossomanalysis.com/psychedelic-research-recap-july-august-2022/ 🧵 1/6

Results from the first trial using psilocybin to treat alcoholism are promising

"Psilocybin administered in combination with psychotherapy produced robust decreases in the percentage of heavy drinking days"

https://twitter.com/blossomact/status/1562701823643127808 2/6

The jury's still out on microdosing

A study using @QuantCitizen was in favour of microdosing but lacked placebo control & blinding

@ETagliazucchi et al found no improvements in well-being, creativity & cognitive function in a double-blind RCT 3/6

New tools for researchers

@drrosalindwatts et al developed & validated the Watts Connectedness Scale to measure feelings of connectedness

Based on the REBUS model, Richard Zeifman et al have begun developing RElaxed Beliefs Questionnaire (REB-Q) 4/6

Could at-home ketamine therapy soon become a reality?

Using real-world evidence, researchers found that sublingual ketamine tablets taken at home reduced measures of depression & anxiety

We looked at what they did here:

https://twitter.com/blossomact/status/1547924309888233473 5/6

In case you were enjoying your vacation this summer and missed the latest developments in psychedelic research - you can check out the full recap 👇

https://blossomanalysis.com/psychedelic-research-recap-july-august-2022/ 6/6